Pasithea Therapeutics (NASDAQ:KTTA) Issues Quarterly Earnings Results

Pasithea Therapeutics (NASDAQ:KTTA) announced its earnings results on Monday. The company reported ($2.41) earnings per share (EPS) for the quarter, Zacks reports.

Pasithea Therapeutics Stock Up 0.8 %

NASDAQ:KTTA opened at $1.25 on Tuesday. Pasithea Therapeutics has a fifty-two week low of $0.92 and a fifty-two week high of $9.25. The firm’s 50 day moving average is $1.67 and its two-hundred day moving average is $2.95.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.